AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Core Insights - AbbVie is set to present new data at the 2025 American Society of Hematology (ASH) Congress, highlighting advancements in research for various blood cancers, including multiple myeloma, follicular lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, acute myeloid leukemia, and amyloidosis [1] - The data will showcase investigational compounds such as etentamig and PVEK, along with approved therapies like EPKINLY and VENCLEXTA, emphasizing AbbVie's commitment to innovation in blood cancer treatment [1][2] Group 1: Research and Development - AbbVie is focusing on a diverse pipeline that includes T-cell engagers, BCL-2 inhibitors, and antibody-drug conjugates, aimed at addressing the heterogeneity of blood cancers [1] - Key data from the epcoritamab and venetoclax-based treatments will demonstrate promising efficacy and safety profiles across multiple hematologic malignancies [1][2] Group 2: Clinical Trial Results - The randomized phase 3 trial EPCORE FL-1 showed that the combination of fixed-duration epcoritamab and rituximab significantly improved progression-free survival (PFS) by 79% compared to standard care [2] - In the CLL17 trial, fixed-duration venetoclax plus obinutuzumab met non-inferiority endpoints compared to continuous ibrutinib monotherapy, with 3-year PFS rates of 81.1% for the venetoclax group [2] Group 3: Presentations at ASH 2025 - Presentations will include results from the EPCORE NHL-2 trial, showcasing high minimal residual disease (MRD) negativity rates in elderly patients with newly diagnosed diffuse large B-cell lymphoma [4] - Data from a phase 1b study of etentamig combined with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma will also be presented, highlighting an overall response rate (ORR) of 81% [5] Group 4: Regulatory Developments - A Biologics License Application (BLA) for PVEK has been submitted to the FDA for the treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm, indicating AbbVie's ongoing efforts to expand its oncology portfolio [5]